Galecto (Galecto) 3-Year FCF Growth Rate : 45.00% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Galecto 3-Year FCF Growth Rate?

Galecto's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.22.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 45.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 7.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 6 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Galecto was 45.00% per year. The lowest was -3.90% per year. And the median was -2.90% per year.

Competitive Comparison of Galecto's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Galecto's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galecto's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galecto's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Galecto's 3-Year FCF Growth Rate falls into.

Galecto 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Galecto (NAS:GLTO) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Galecto 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Galecto's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Galecto (Galecto) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galecto Inc (NAS:GLTO) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.galecto.com

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis-related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Executives

Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Bertil Lindmark	officer: Chief Medical Officer	C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Hans T. Schambye	director, officer: Chief Executive Officer	C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Stephanie Oestreich	officer: Chief Business Officer	75 STATE STREET, SUITE 100, BOSTON MA 02109
Jonathan Freve	officer: Chief Financial Officer	C/O SPRING BANK PHARMACEUTICALS, INC., 113 CEDAR STREET, STE S-7, MILFORD MA 01757
Garrett Winslow	officer: General Counsel	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Anne Prener	director	C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139
Dallas Jayson Donald Alexander	director	AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Chau Quang Khuong	director, 10 percent owner	C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Stephan Christgau	director	C/O CASTLE & MORGAN HOLDINGS, INC., 425 MARKET STREET, SUITE 2230, SAN FRANCISCO CA 94105
Soren Moller	director	C/O NOVO HOLDINGS A/S, TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Anders Pedersen	officer: Chief Operating Officer	C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Orbimed Advisors Israel Ii Ltd	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Israel Gp Ii, L.p.	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022